It is expected the human growth hormone biogenerics will be able to enter the UK by the end of this year, and in the United States by 2009.
The global market for biogenerics such as human growth hormone, CSF, and Epoeting, are expected to reach over $20 Billion.
The companies that are responsible for introduction of biogenerics include big names such as Sandoz, Teva, and BioPartners. With their introduction into UK society, the biogeneric companies will be subjected to a regulatory process for the 25 biogeneric companies. The FDA is expected to approve the use of its first biogeneric product in 2009, with the hopeful introduction of biogeneric insulin and growth hormone.
However, the introduction of biogenerics, the general public will require a different type of marketing strategy that was previously used. The strategy will need to focus more on gaining the patient’s trust and support while trying to help consumers see the advantages of using a biogeneric product.
